Accueil   Agenda - News   Toutes les news ORPHELIA Pharma and Clinigen sign an agreement to supply Kigabeq®

ORPHELIA Pharma and Clinigen sign an agreement to supply Kigabeq®

 

 

Paris and Lyon, on July 21st, 2021 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of pediatric and orphan drugs and Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical Products and Services company, announce that they have signed an exclusive agreement to manage the supply and distribution of Kigabeq® into unlicensed markets.

 

Kigabeq® was granted a European Paediatric Use Marketing Authorization (PUMA) in September 2018 and is currently approved for the treatment of infantile spasms (West Syndrome) and pharmaco-resistant focal-onset seizures (partial seizures).

 

Under the terms of the agreement, Clinigen will provide access to Kigabeq® 500 mg and 100 mg soluble tablets into markets where Kigabeq® is not commercially available. Clinigen will manage all elements of the supply including healthcare practitioner enquiry management, regulatory oversight, logistics and access management. The agreement currently covers all global territories except for USA, China, EU, UK and Bangladesh.

 

Lire le communiqué de presse